- Admin
- #1
Regenxbio (NASDAQ: RGNX) is a clinical-stage biotech company that focuses on gene therapies based on its NAV Technology Platform. On Tuesday, the company moved a step closer with its "5x25 plan" of turning five of the therapies in its pipeline into marketed products by 2025. The Food and Drug Administration (FDA) granted fast track designation for Regenxbio's RGX-202, a potential onetime gene therapy to treat Duchenne muscular dystrophy.